Apnimed goes public to fund its sleep apnea treatment

Apnimed, a manufacturer of sleep apnea drugs, files for an IPO in the United States.

Published 3j1 sourceNotableupdated 2j

≈ 20sSpeed

The fact

The biotech aims to raise funds to accelerate the development of its AD109 treatment.

Its market debut could value the company at over one billion dollars.

Explore this topic

Cross-sources — 1 source

Auto-synthesis from 1 media source · identified on July 10, 2026